Izhakian S, Pertzov B, Rosengarten D, Kramer MR. Successful treatment of acute relapse of chronic eosinophilic pneumonia with benralizumab and without corticosteroids: A case report . World J Clin Cases 2022; 10(18): 6105-6109 [PMID: 35949821 DOI: 10.12998/wjcc.v10.i18.6105]
Corresponding Author of This Article
Shimon Izhakian, MD, PhD, Doctor, Pulmonary Institute, Rabin Medical Center, No. 39 Jabotinski St., Petach Tikva 49100, Israel. shimixyz@gmail.com
Research Domain of This Article
Respiratory System
Article-Type of This Article
Case Report
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Jun 26, 2022; 10(18): 6105-6109 Published online Jun 26, 2022. doi: 10.12998/wjcc.v10.i18.6105
Successful treatment of acute relapse of chronic eosinophilic pneumonia with benralizumab and without corticosteroids: A case report
Shimon Izhakian, Barak Pertzov, Dror Rosengarten, Mordechai R Kramer
Shimon Izhakian, Barak Pertzov, Dror Rosengarten, Mordechai R Kramer, Pulmonary Institute, Rabin Medical Center, Petach Tikva 49100, Israel
Shimon Izhakian, Barak Pertzov, Dror Rosengarten, Mordechai R Kramer, Affiliated to Sackler Faculty of Medicine, Tel Aviv University, Ramat Aviv, Israel
Author contributions: Izhakian S and Rosengarten D contributed to the acquisition and interpretation of the data; Pertzov B and Kramer MR contributed to the critical revision of the manuscript for important intellectual content; all authors contributed to the drafting of the manuscript and approved the final version.
Informed consent statement: Written informed consent was obtained from the patient for publication of this manuscript and any accompanying images.
Conflict-of-interest statement: The authors declare that they have no conflicts of interest related to this work.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Shimon Izhakian, MD, PhD, Doctor, Pulmonary Institute, Rabin Medical Center, No. 39 Jabotinski St., Petach Tikva 49100, Israel. shimixyz@gmail.com
Received: April 14, 2021 Peer-review started: April 14, 2021 First decision: September 28, 2021 Revised: November 5, 2021 Accepted: May 5, 2022 Article in press: May 5, 2022 Published online: June 26, 2022 Processing time: 428 Days and 12.4 Hours
Core Tip
Core Tip: Chronic eosinophilic pneumonia (CEP) is an idiopathic pulmonary disease, characterized by marked eosinophil accumulation in the pulmonary parenchyma. Currently, the mainstay of CEP treatment is corticosteroids. However, relapse is common, requiring long-term use of corticosteroids, with the risk of significant treatment-related adverse effects. Herein, we describe a patient with an acute CEP relapse, successfully treated with benralizumab alone, without corticosteroids. Currently, only three patients with acute relapse of CEP, were reported successfully treated with benralizumab alone, without corticosteroids. This therapy option may be particularly beneficial for patients who have previously suffered serious adverse effects from or have any contraindications to chronic corticosteroid treatment.
